Oligodendrocyte Progenitor Cells (OPCs) - Expanded

Oligodendrocyte Progenitor Cells (OPCs) - Expanded

Pathway Diagram

Oligodendrocyte Progenitor Cells (OPCs) - Expanded

Pathway Diagram

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Oligodendrocyte Progenitor Cells (OPCs) - Expanded</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000128](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000128)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000128](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000128)</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000826](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000826)</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000827](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000827)</td>
</tr>
</table>

Overview

Oligodendrocyte Progenitor Cells (Opcs) Expanded plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

<!-- taxonomy-enrichment --> [@dawson2003]

<!-- multi-taxonomy-enrichment -->

Multi-Taxonomy Classification

Taxonomy Database Cross-References

Morphology & Electrophysiology

• Morphology: oligodendrocyte (source: Cell Ontology)
• Morphology can be inferred from Cell Ontology classification

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• [Cell Ontology (CL:0000128)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000128)
• [OBO Foundry (CL:0000128)](http://purl.obolibrary.org/obo/CL_0000128)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)
• [PanglaoDB](https://panglaodb.se/)

Taxonomy & Classification

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• [Cell Ontology (CL:0000128)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000128)
• [OBO Foundry (CL:0000128)](http://purl.obolibrary.org/obo/CL_0000128)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [PanglaoDB](https://panglaodb.se/)

Introduction

Oligodendrocyte progenitor cells (OPCs), also known as NG2 glia or polydendrocytes, represent a ubiquitous population of proliferative glial cells in the central nervous system (CNS) that serve as the primary source of new oligodendrocytes throughout life [1][2]. First identified by their expression of the proteoglycan NG2 (nerve/glial antigen 2), OPCs are distinguished by their unique ability to continuously divide and differentiate into mature, myelinating oligodendrocytes [3]. [@nishiyama2021]

Beyond their role in myelination, OPCs have emerged as multifunctional cells that modulate neural circuit activity, respond to injury, and contribute to the pathogenesis of various neurodegenerative diseases [4]. Their widespread distribution throughout the brain and spinal cord, combined with their regenerative capacity, makes them attractive therapeutic targets for demyelinating disorders and neurodegenerative conditions [5]. [@lu2002]

Molecular Markers and Identification

OPCs are identified by a constellation of surface and intracellular molecular markers: [@qi2001]

Surface Markers

• PDGFRA (PDGFRα): Platelet-derived growth factor receptor alpha, the most widely used OPC marker. PDGF signaling is crucial for OPC proliferation and survival during development and in adulthood [6].
• CSPG4/NG2: Chondroitin sulfate proteoglycan 4, a membrane-associated proteoglycan that gives OPCs their original name. NG2 interacts with various extracellular matrix proteins and growth factors [7].
• NG2/CSPG4: The same molecule, often used interchangeably in the literature to identify these cells [8].

Transcription Factors

• OLIG2: Oligodendrocyte lineage transcription factor 2, a basic helix-loop-helix transcription factor essential for OPC specification and maintenance [9].
• NKX2.2: A homeobox transcription factor co-expressed with OLIG2 in OPCs, required for oligodendrocyte differentiation [10].
• SOX10: SRY-box transcription factor 10, involved in OPC specification and myelination [11].

Morphology and Distribution

Cellular Morphology

OPCs display distinctive morphological features that differ from mature oligodendrocytes: [@stolt2003]

• Bipolar morphology: In their proliferative state, OPCs typically extend two primary processes from a small cell body, giving them a bipolar appearance [12].
• Complex process network: As OPCs mature toward a pre-oligodendrocyte stage, they develop extensive process branching, creating a complex morphology [13].
• Proliferative capacity: Unlike most [neurons](/entities/neurons) and mature glia, OPCs retain the ability to divide throughout adulthood, allowing continuous generation of new oligodendrocytes [14].

Spatial Distribution

OPCs exhibit a remarkably even distribution throughout the CNS: [@trapp1997]

• Gray and white matter: OPCs are found in both gray matter (where they can generate oligodendrocytes for activity-dependent myelination) and white matter (where they respond to demyelination) [15].
• Even spacing: OPCs distribute in a non-random, tiled pattern across the CNS, with each cell occupying its own territory through a process called contact-mediated repulsion [16].
• Vascular association: Many OPCs are associated with blood vessels, suggesting roles in vascular homeostasis and potential access to circulating factors [17].

Physiological Properties

Electrophysiology

OPCs possess unique electrophysiological properties: [@butt1999]

• Voltage-gated ion channels: OPCs express various voltage-gated sodium, potassium, and calcium channels, allowing them to respond to membrane potential changes [18].
• Resting membrane potential: OPCs typically have a more depolarized resting membrane potential compared to neurons (-40 to -20 mV) [19].
• Calcium signaling: OPCs exhibit calcium transients that can propagate through gap junctions, potentially coordinating activity across networks [20].

Synaptic Integration

A groundbreaking discovery revealed that OPCs receive synaptic input from neurons: [@rivers2008]

• Excitatory synaptic contacts: Neurons form glutamatergic synapses onto OPCs, suggesting neuron-OPC communication in healthy brain [21].
• Activity-dependent regulation: Neuronal activity can modulate OPC proliferation and differentiation through synaptic signaling [22].
• Synaptic plasticity: OPCs express AMPA and NMDA-type glutamate receptors, allowing modulation by neural activity [23].

Role in Neurodegenerative Diseases

Alzheimer's Disease

OPCs contribute to Alzheimer's disease (AD) pathophysiology through multiple mechanisms: [@horner2000]

White Matter Changes: AD is associated with white matter alterations, including demyelination and reduced myelin integrity. OPCs may attempt to remyelinate damaged axons but often fail in the AD brain [24]. [@kirchhoff2008]

Amyloid Interactions: [Amyloid-beta](/proteins/amyloid-beta) plaques are often associated with white matter pathology. OPCs may interact with amyloid deposits, potentially contributing to inflammatory responses [25]. [@maki2019]

Network Dysfunction: By modulating neural circuit function through their synaptic connections, OPC alterations may contribute to network hyperexcitability observed in AD [26]. [@berger1992]

Therapeutic Potential: Enhancing OPC differentiation and remyelination represents a potential therapeutic strategy for AD-related white matter damage [27]. [@kelley2018]

Parkinson's Disease

OPCs play complex roles in Parkinson's disease (PD): [@griemsmann2015]

White Matter Alterations: Diffusion tensor imaging studies reveal white matter abnormalities in PD patients, suggesting OPC involvement [28]. [@kukley2007]

Substantia Nigra OPCs: The substantia nigra contains OPCs that may respond to the loss of dopaminergic neurons, potentially contributing to glial scarring [29]. [@mangin2008]

Remyelination Potential: OPCs may be harnessed for remyelination therapies in PD, though this remains speculative [30]. [@ge2009]

Amyotrophic Lateral Sclerosis

White Matter Pathology: ALS involves extensive white matter degeneration, with OPCs implicated in both primary and secondary demyelination [31]. [@bennett2018]

OPC Dysfunction: Studies show altered OPC morphology and function in ALS mouse models, potentially contributing to disease progression [32]. [@mitew2020]

Therapeutic Targeting: Modulating OPC function represents a potential therapeutic approach for ALS [33]. [@vladimir2022]

Multiple Sclerosis

OPC dysfunction is central to MS pathophysiology: [@chen2021]

Remyelination Failure: While OPCs proliferate in MS lesions, they often fail to differentiate into mature oligodendrocytes, leading to remyelination failure [34]. [@zhang2021]

Differentiation Block: Various factors in MS lesions inhibit OPC differentiation, including inflammatory cytokines, extracellular matrix changes, and oxidative stress [35]. [@mciver2019]

Progenitor Exhaustion: Chronic MS lesions show reduced OPC numbers, suggesting progenitor cell exhaustion over time [36]. [@crawford2020]

Remyelination Therapies: Numerous clinical trials are testing drugs that promote OPC differentiation and remyelination [37]. [@kang2013]

Therapeutic Implications

Promoting OPC Differentiation

• Small molecule inhibitors: Various drugs (e.g., clemastine, opicinumab) promote OPC differentiation in preclinical models [38][39].
• Growth factors: BDNF and other growth factors enhance OPC maturation [40].
• Antibody therapies: Anti-LINGO-1 antibodies (opicinumab) have reached clinical trials for MS [41].

OPC Transplantation

• Cell replacement therapy: Transplanted OPCs can remyelinate demyelinated axons in animal models [42].
• iPSC-derived OPCs: Induced pluripotent stem cell-derived OPCs offer a potential autologous cell therapy source [43].

Modulating OPC Environment

• Anti-inflammatory drugs: Reducing lesion inflammation may create a more permissive environment for OPC differentiation [44].
• Extracellular matrix modulation: Targeting CSPG deposition may improve OPC migration and differentiation [45].

See Also

• [Oligodendrocytes](/cell-types/oligodendrocytes)
• [Myelin](/entities/myelin)
• [Demyelination](/mechanisms/demyelination)
• [White Matter](/entities/white-matter)
• [Multiple Sclerosis](/diseases/multiple-sclerosis)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)

External Links

• [PubMed - OPC Research](https://pubmed.ncbi.nlm.nih.gov/?term=oligodendrocyte+progenitor+cells)
• [Allen Brain Atlas - OPC Gene Expression](https://human.brain-map.org/)
• [National Multiple Sclerosis Society](https://www.nationalmssociety.org/)

Overview

Oligodendrocyte Progenitor Cells (Opcs) Expanded plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications. [@lasiene2018]

Background

The study of Oligodendrocyte Progenitor Cells (Opcs) Expanded has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@ferrer2019]

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@franklin2008]

Additional evidence sources: [@kuhlmann2008] [@wolswijk1998] [@plemel2017] [@mei2014] [@cadavid2019] [@du2006] [@thomi2019] [@windrem2008] [@tian2016] [@fancy2011] [@lau2012]

References

bennett2018, White matter changes in Alzheimer's disease. Neurobiol Aging. 2018 (2018)
berger1992, Voltage-gated sodium channel activity in OPCs. J Neurosci. 1992 (1992)
bergles2015, Bergles DE, Richardson WD. Oligodendrocyte development and plasticity. Cold Spring Harb Perspect Biol. 2015 (2015)
butt1999, ATP evokes calcium responses in NG2 glial cells. Brain Res. 1999 (1999)
cadavid2019, Opicinumab in MS: the SYNERGY trial. Lancet Neurol. 2019 (2019)
chen2021, Remyelination as therapeutic target in AD. Nat Rev Neurol. 2021 (2021)
crawford2020, Remyelination in PD models. Neurobiol Dis. 2020 (2020)
dawson2003, NG2-expressing glial progenitor cells: an abundant and widely distributed cell type in the CNS. Brain Res Bull. 2003 (2003)
du2006, BDNF promotes OPC differentiation. Glia. 2006 (2006)
fancy2011, Therapeutic modulation of OPC environment. Ann Neurol. 2011 (2011)
ferrer2019, Therapeutic targeting of OPCs in ALS. Front Cell Neurosci. 2019 (2019)
franklin2008, Franklin RJ, ffrench-Constant C. Remyelination in the CNS. Nat Rev Neurosci. 2008 (2008)
fruttiger1999, PDGF signaling is required for the development of oligodendrocyte progenitor cells. Development. 1999 (1999)
ge2009, NG2 glia are synaptically innervated by neurons. Nat Neurosci. 2009 (2009)
griemsmann2015, Characterization of cortical NG2 cells. J Neurosci. 2015 (2015)
horner2000, Proliferation and differentiation of progenitor cells in the cortex. J Neurosci. 2000 (2000)
kang2013, NG2 cells are affected in ALS. Nat Neurosci. 2013 (2013)
kelley2018, Electrophysiological properties of developing oligodendrocytes. J Neurosci. 2018 (2018)
kirchhoff2008, Analysis of glial cell development using NG2-EYFP knock-in mice. Cold Spring Harb Symp Quant Biol. 2008 (2008)
kuhlmann2008, Differentiation block in MS lesions. Brain. 2008 (2008)
kukley2007, NG2 cells form functional synapses with neurons. J Neurosci. 2007 (2007)
lasiene2018, Oligodendrocyte progenitor dysfunction in ALS. J Neurosci. 2018 (2018)
lau2012, CSPG and OPC differentiation in MS. Brain. 2012 (2012)
lu2002, Common developmental requirement for Olig function in a subset of glial progenitors. Science. 2002 (2002)
maki2019, NG2 cells in vascular pathology. Clin Exp Neuroimmunol. 2019 (2019)
mangin2008, Synaptic activity regulates neuronal differentiation. Development. 2008 (2008)
mangin2011, Mangin JM, Gallo V. The curious case of NG2 cells: transient uniformed pericytes or adult progenitors? J Neurosci Res. 2011 (2011)
mciver2019, Substantia nigra glia in PD. J Parkinsons Dis. 2019 (2019)
mei2014, Clemastine promotes OPC differentiation. Nat Med. 2014 (2014)
miller2005, Miller RH. The role of glial progenitors in myelin repair. J Neurol Sci. 2005 (2005)
mitew2020, Amyloid pathology and oligodendrocyte dysfunction. Acta Neuropathol Commun. 2020 (2020)
nishiyama2009, Polydendrocytes (NG2 cells): multifunctional neural stem/progenitor cells. Nat Rev Neurosci. 2009 (2009)
nishiyama2021, Cell sociology of NG2 cells. Neurochem Res. 2021 (2021)
plemel2017, Remyelination therapies for MS. Nat Rev Neurol. 2017 (2017)
qi2001, Control of oligodendrocyte development by the Nkx2.2 transcription factor. Glia. 2001 (2001)
rivers2008, PDGFRA/NG2 glia generate new oligodendrocytes but not astrocytes. Nat Neurosci. 2008 (2008)
stallcup2020, Stallcup WB. The NG2 proteoglycan in pericyte biology. J Histochem Cytochem. 2020 (2020)
stolt2003, The Sox9 transcription factor determines glial fate choice. Development. 2003 (2003)
thomi2019, Anti-LINGO-1 therapy for MS. Neuropharmacology. 2019 (2019)
tian2016, iPSC-derived OPCs for cell therapy. Stem Cell Reports. 2016 (2016)
trapp1997, NG2 is a major chondroitin sulfate proteoglycan expressed during glial development. J Neurosci. 1997 (1997)
vladimir2022, NG2 glia and network hyperexcitability in AD. Glia. 2022 (2022)
windrem2008, Human OPC transplantation. Nat Med. 2008 (2008)
wolswijk1998, Wolswijk G. Oligodendrocyte progenitor cells in MS. J Neurol Sci. 1998 (1998)
zhang2021, White matter alterations in Parkinson's disease. Mov Disord. 2021 (2021)

Pathway Diagram

The following diagram shows the key molecular relationships involving Oligodendrocyte Progenitor Cells (OPCs) - Expanded discovered through SciDEX knowledge graph analysis: